Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Camélia Benlabiod, Maira da Costa Cacemiro, PhD, Thomas Balligand, MD, Barbara Panneau-Schmaltz, PhD, Delphine Muller, Laure Touchard, Patrick Gonin, DVM, Jean-Luc Villeval, PhD, Stefan N Constantinescu, MD PhD, Hana Raslova, PhD, William Vainchenker, MD PhD, Isabelle Plo, Caroline Marty, PhD

Blood (2019) 134 (Supplement_1): 311.

https://doi.org/10.1182/blood-2019-127918

Published: 2019

Journal Articles

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

Blood (2019) 134 (Supplement_1): 5288.

https://doi.org/10.1182/blood-2019-126434

Published: 2019

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

Matthieu Mosca, PhDstudent, Lamia Lamrani, PhD, Christophe Marzac, MD, Amandine Tisserand, Valérie Edmond, PhD, Tracy Dagher, PhDstudent, Mira El-Khoury, PhD, Caroline Marty, PhD, Hugo Campario, PharmD, Nicole Casadevall, MD, Eric Solary, MD PhD, Hana Raslova, PhD, Bruno Cassinat, PharmD, PhD, Stefan N Constantinescu, MD, Jean-Jacques Kiladjian, MD PhD, Francois Girodon, MD PhD, Jean-Luc Villeval, PhD, William Vainchenker, MD PhD, Isabelle Plo, PhD

Blood (2018) 132 (Supplement 1): 4333.

https://doi.org/10.1182/blood-2018-99-114744

Published: 2018

Journal Articles

JAK2 V617F Dimerizes Homodimeric Cytokine Receptors Cytosolic Domains By Requiring Pseudokinase Domain Residues That Promote JAK2 Dimerization and Oncogenic Activity

Emilie Leroy, Thomas Balligand, MD, Stefan N Constantinescu, MD

Blood (2018) 132 (Supplement 1): 50.

https://doi.org/10.1182/blood-2018-99-111336

Published: 2018

Journal Articles

JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils

Cristina Mambet, MD, Jean-Philippe Defour, BPharm, PhD, Olga Babosova, M.Sc., Emilie Leroy, Laura Necula, PhD, Oana Stanca, MD, Aurelia Tatic, MD, Daniel Coriu, MD, Monika Belickova, PhD, Barbora Kralova, MSc, Lucie Lanikova, PhD, Pascale Saussoy, Violaine Havelange, Carmen C. Diaconu, PhD, Vladimir Divoky, PhD, Stefan N Constantinescu, MD

Blood (2018) 132 (Supplement 1): 3066.

https://doi.org/10.1182/blood-2018-99-117019

Published: 2018

Journal Articles

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Blood (2018) 132 (Supplement 1): 4.

https://doi.org/10.1182/blood-2018-99-118348

Published: 2018

Journal Articles

Rare Type 1-like and Type 2-like Calrecticulin Mutants Induce Similar Myeloproliferative Neoplasms Than Type 1 and Type 2 Mutants in Mice

Katte Rao Toppaldoddi, Maira da Costa Cacemiro, Olivier Bluteau, PhD, Amélie Pioch, Barbara Panneau-Schmaltz, PhD, Delphine Muller, Nicole Casadevall, MD, Hana Raslova, PhD, Stefan N. Constantinescu, MD PhD, Isabelle Plo, William Vainchenker, MD PhD, Caroline Marty, PhD

Blood (2017) 130 (Supplement 1): 1665.

https://doi.org/10.1182/blood.V130.Suppl_1.1665.1665

Published: 2017

Journal Articles

A Novel JAK2 Mutation Confers Cytokine-Independence in the Absence of a Type I Dimeric Cytokine Receptor

Ami B. Patel, MD, Anca Franzini, PhD, Emilie Leroy, PhD, Dongqing Yan, Anna M. Eiring, PhD, Stefan N. Constantinescu, MD PhD, Thomas O'Hare, PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 4212.

https://doi.org/10.1182/blood.V130.Suppl_1.4212.4212

Published: 2017

Journal Articles

New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia

Florence Pasquier, MD PhD, Caroline Marty, PhD, Frédérique Verdier, PhD, Sarah Grosjean, MBiol, Claude Préhu, MD, Stefan N. Constantinescu, MD PhD, Hana Raslova, PhD, Nicole Casadevall, MD, William Vainchenker, MD PhD, Christine Bellanné-Chantelot, PharmD, PhD, Isabelle Plo, PhD

Blood (2016) 128 (22): 631.

https://doi.org/10.1182/blood.V128.22.631.631

Published: 2016

Journal Articles

Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells

Mira EL Khoury, Gaelle Vertenoeil, Caroline Marty, Christophe Marzac, Matthieu Mosca, Christian Pecquet, PhD, Fabrizia Favale, Robert Kralovics, Najet Debili, Nicole Casadevall, MD, Hana Raslova, PhD, Stefan N. Constantinescu, MD PhD, Isabelle Plo, William Vainchenker, MD PhD

Blood (2016) 128 (22): 1959.

https://doi.org/10.1182/blood.V128.22.1959.1959

Published: 2016

Journal Articles

Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms

Jelena D Milosevic Feenstra, PhD, Harini Nivarthi, PhD, Heinz Gisslinger, MD, Emilie Leroy, Elisa Rumi, MD, Ilyas Chachoua, Klaudia Bagienski, Blanka Kubesova, MSc, Daniela Pietra, PhD, Bettina Gisslinger, Roland Jäger, PhD, Doris Chen, PhD, Tiina Berg, B.Sc., Martin Schalling, MSc, Michael Schuster, PhD, Christoph Bock, PhD, Stefan N. Constantinescu, MD PhD, Mario Cazzola, MD, Robert Kralovics, PhD

Blood (2015) 126 (23): 606.

https://doi.org/10.1182/blood.V126.23.606.606

Published: 2015

Journal Articles

Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms

Stefan N Constantinescu, MD PhD Prof., Jean-Philippe Defour, BPharm,, Celine Mouton, Isabelle Plo, William Vainchenker, MD PhD, Jean-Luc Villeval, PhD, Thomas Michiels, MD PhD, Judith Staerk, Christian Pecquet, PhD

Blood (2014) 124 (21): 820.

https://doi.org/10.1182/blood.V124.21.820.820

Published: 2014

Journal Articles

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Blood (2014) 124 (21): 1823.

https://doi.org/10.1182/blood.V124.21.1823.1823

Published: 2014

Journal Articles

Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis

Caroline Marty, PhD, Nivarthi Harini, Christian Pecquet, PhD, Ilyas Chachoua, Vitalina Gryshkova, PhD, Jean-Luc Villeval, PhD, Stefan N. Constantinescu, MD PhD, Robert Kralovics, PhD, William Vainchenker, MD, PhD, Isabelle Plo

Blood (2014) 124 (21): 157.

https://doi.org/10.1182/blood.V124.21.157.157

Published: 2014

Journal Articles

JAK2 E846D Germline Mutation Associated with Erythrocytosis Causes Increased and Prolonged Epo-Induced Activation of STAT5

Katarina Kapralova, MSc, Monika Horvathova, PhD, Jana Kucerova, PhD, Dagmar Pospisilova, MD PhD, Emilie Leroy, Stefan N. Constantinescu, MD PhD, Vladimir Divoky, PhD

Blood (2014) 124 (21): 4008.

https://doi.org/10.1182/blood.V124.21.4008.4008

Published: 2014

Journal Articles

Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and HSP90 Inhibitors

Caroline Marty, Ph.D, Cecile Saint-martin, Christian Pecquet, PhD, Sarah Grosjean, Joseph Saliba, PhD Student, Celine Mouton, Leroy Emilie, Ashot S. Harutyunyan, Jean-François Abgrall, Remy Favier, Eric Solary, Robert Kralovics, PhD, Stefan N. Constantinescu, MD, PhD, Albert Najman, MD, William Vainchenker, MD, PhD, Isabelle Plo, Ph.D, Christine Bellanné-Chantelot

Blood (2013) 122 (21): 1603.

https://doi.org/10.1182/blood.V122.21.1603.1603

Published: 2013

Journal Articles

Controlling Thrombopoietin Receptor Dimerization, Orientation and Activation Via Tryptophan 515

Jean-Philippe Defour, BPharm, Miki Itaya, MSc., Vitalina Gryshkova, PhD, Ian Brett, MSc., Christian Pecquet, PhD, Takeshi Sato, PhD, Steven O. Smith, PhD, Stefan N. Constantinescu, MD, PhD

Blood (2012) 120 (21): 3449.

https://doi.org/10.1182/blood.V120.21.3449.3449

Published: 2012

Journal Articles

Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms

Meng Ling Choong, PhD, Christian Pecquet, PhD, Shi Jing Tai, Jacklyn WY Yong, PhD, Vishal Pendharkar, SiFang Wang, Jean-Philippe Defour, BPharm, Carmen C. Diaconu, PhD, Kanda Sangthongpitag, PhD, Jean-Luc Villeval, PhD, William Vainchenker, MD, PhD, Stefan N. Constantinescu, MD, PhD, May Ann Lee, PhD

Blood (2012) 120 (21): 180.

https://doi.org/10.1182/blood.V120.21.180.180

Published: 2012

Journal Articles

ALL-Associated JAK1 Mutants Activate the JAK/STAT Pathway Via IL-9Rα Homodimers

Tekla Hornakova, Judith Staerk, Yohan Royer, Elisabetta Flex, Marco Tartaglia, Stefan N. Constantinescu, MD, PhD, Jean-Christophe Renauld, Laurent Knoops

Blood (2008) 112 (11): 2848.

https://doi.org/10.1182/blood.V112.11.2848.2848

Published: 2008

NARROW

Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage

Results from Treatment of a Large Cohort of ATL Patients from a Country with High HTLV1 Prevalence

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Differential Impact of Interferon Alpha on JAK2 V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN

JAK2 V617F Dimerizes Homodimeric Cytokine Receptors Cytosolic Domains By Requiring Pseudokinase Domain Residues That Promote JAK2 Dimerization and Oncogenic Activity

JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Rare Type 1-like and Type 2-like Calrecticulin Mutants Induce Similar Myeloproliferative Neoplasms Than Type 1 and Type 2 Mutants in Mice

A Novel JAK2 Mutation Confers Cytokine-Independence in the Absence of a Type I Dimeric Cytokine Receptor

New Insights into Mechanisms of Erythropoietin Receptor Mutations in Primary Familial and Congenital Polycythemia

Calreticulin Mutants Induce an Early Clonal Dominance and a Megakaryocytic Phenotype through the Activation of MPL/JAK2 Pathway in Human Primary Cells

Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms

Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms

Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis

JAK2 E846D Germline Mutation Associated with Erythrocytosis Causes Increased and Prolonged Epo-Induced Activation of STAT5

Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and HSP90 Inhibitors

Controlling Thrombopoietin Receptor Dimerization, Orientation and Activation Via Tryptophan 515

Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms

ALL-Associated JAK1 Mutants Activate the JAK/STAT Pathway Via IL-9Rα Homodimers

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only